Title:
NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2013/162298
Kind Code:
A1
Abstract:
The present invention relates to novel beta-alanine derivatives, to the pharmaceutically acceptable salts thereof, and to a pharmaceutical composition comprising same as an active ingredient. The novel beta-alanine derivatives and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, and therefore can be effectively used as a pharmaceutical composition for preventing or treating various diseases relating to lipid metabolism belonging to the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.
Inventors:
AHN JIN HEE (KR)
KANG SEUNG KYU (KR)
H S PAGIRE (KR)
RHEE SANG DAL (KR)
KIM KI YOUNG (KR)
JUNG WON HOON (KR)
BAE MYUNG-AE (KR)
SONG JIN SOOK (KR)
CHAE CHONG HAK (KR)
AHN SUNG HOON (KR)
KIM KWANG-ROK (KR)
KANG SEUNG KYU (KR)
H S PAGIRE (KR)
RHEE SANG DAL (KR)
KIM KI YOUNG (KR)
JUNG WON HOON (KR)
BAE MYUNG-AE (KR)
SONG JIN SOOK (KR)
CHAE CHONG HAK (KR)
AHN SUNG HOON (KR)
KIM KWANG-ROK (KR)
Application Number:
PCT/KR2013/003557
Publication Date:
October 31, 2013
Filing Date:
April 25, 2013
Export Citation:
Assignee:
KOREA RES INST CHEM TECH (KR)
HANDOK PHARMACEUTICALS CO LTD
HANDOK PHARMACEUTICALS CO LTD
International Classes:
A61K31/16; C07C233/25; A61P1/16; A61P3/04
Domestic Patent References:
| WO2003099765A1 | 2003-12-04 | |||
| WO1999026921A1 | 1999-06-03 | |||
| WO2011123401A1 | 2011-10-06 |
Other References:
LAU, JESPER ET AL.: "New beta-alanine derivatives are orally available glucagon receptor antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, 2007, pages 113 - 128, XP009120616
LOW, ROBERT L. ET AL.: "Discovery of PF-04620110, a potent, selective, and orally bioavailable inhibitor of DGAT-1", ACS MEDICINAL CHEMISTRY LETTERS, vol. 2, 2011, pages 407 - 412, XP055099907
REAVEN GM, DIABETES, vol. 37, 1988, pages 1595 - 607
FREEMAN B.A. ET AL., LAB INVEST., vol. 47, 1982, pages 412 - 26
KAWAMURA M. ET AL., J CLIN. INVEST., vol. 94, 1994, pages 771 - 8
EVA HERKER ET AL.: "Efficient Hepatitis C Virus Particle Formation Requires Diacylglycerol Acyltransferase-1", NATURE MEDICINE, vol. 16, 2010, pages 1295 - 1298
"Remington's Pharmaceutical Sciences", 1995
See also references of EP 2842938A4
LOW, ROBERT L. ET AL.: "Discovery of PF-04620110, a potent, selective, and orally bioavailable inhibitor of DGAT-1", ACS MEDICINAL CHEMISTRY LETTERS, vol. 2, 2011, pages 407 - 412, XP055099907
REAVEN GM, DIABETES, vol. 37, 1988, pages 1595 - 607
FREEMAN B.A. ET AL., LAB INVEST., vol. 47, 1982, pages 412 - 26
KAWAMURA M. ET AL., J CLIN. INVEST., vol. 94, 1994, pages 771 - 8
EVA HERKER ET AL.: "Efficient Hepatitis C Virus Particle Formation Requires Diacylglycerol Acyltransferase-1", NATURE MEDICINE, vol. 16, 2010, pages 1295 - 1298
"Remington's Pharmaceutical Sciences", 1995
See also references of EP 2842938A4
Attorney, Agent or Firm:
KWON, Oh-Sig et al. (Hanbat-daero Seo-gu, Daejeon 302-828, KR)
Download PDF: